{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:24:55Z","timestamp":1778811895911,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40264-021-01091-x","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T11:32:23Z","timestamp":1628595143000},"page":"987-998","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020"],"prefix":"10.1007","volume":"44","author":[{"given":"Elena","family":"Rocca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oskar","family":"Gauffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Savage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara Hedfors","family":"Vidlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2799-9374","authenticated-orcid":false,"given":"Birgitta","family":"Grundmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"key":"1091_CR1","unstructured":"World Health Organization. Descriptive analysis of COVID-19-related spontaneous reports from VigiBase: interim results. 2020. https:\/\/www.who.int\/medicines\/regulation\/medicines-safety\/COVID19-PV-update4.pdf?ua=1. Accessed 1 June 2020."},{"key":"1091_CR2","doi-asserted-by":"crossref","unstructured":"Machhi J, Herskovitz J, Senan AM, Dutta D, Nath B, Oleynikov MD, et al. The Natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. J Neuroimmune Pharmacol. 2020;15(3):359\u2013386.","DOI":"10.1007\/s11481-020-09944-5"},{"key":"1091_CR3","first-page":"91","volume":"94","author":"J Yang","year":"2020","unstructured":"Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2020;94:91\u20135.","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis."},{"key":"1091_CR4","doi-asserted-by":"crossref","unstructured":"Jin J-M, Bai P, He W, Wu F, Liu X-F, Han D-M, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health [Internet]. 2020;8:152.","DOI":"10.3389\/fpubh.2020.00152"},{"key":"1091_CR5","doi-asserted-by":"crossref","unstructured":"Osuchowski MF, Aletti F, Cavaillon J-M, Floh\u00e9 SB, Giamarellos-Bourboulis EJ, Huber-Lang M, et al. SARS-CoV-2\/COVID-19: Evolving reality, global response, knowledge gaps, and opportunities. Shock. 2020;54(4):416\u201337.","DOI":"10.1097\/SHK.0000000000001565"},{"key":"1091_CR6","unstructured":"European Medicines Agency. Summary of product characteristics for Veklury. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/other\/veklury-product-information-approved-chmp-25-june-2020-pending-endorsement-european-commission_en.pdf. Accessed 21 Sept 2020."},{"key":"1091_CR7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/phar.2429","volume":"40","author":"SCJ Jorgensen","year":"2020","unstructured":"Jorgensen SCJ, Kebriaei R, Dresser LD. Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Pharmacother J Hum Pharmacol Drug Ther. 2020;40:659\u201371.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther."},{"key":"1091_CR8","doi-asserted-by":"crossref","unstructured":"Elsawah HK, Elsokary MA, Abdallah MS, ElShafie AH. Efficacy and safety of remdesivir in hospitalized Covid-19 patients: Systematic review and meta-analysis including network meta-analysis. Rev Med Virol. 2021;31(4):e2187.","DOI":"10.1002\/rmv.2187"},{"key":"1091_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"Consortium WST","year":"2021","unstructured":"Consortium WST. Repurposed antiviral drugs for Covid-19 \u2014 interim WHO solidarity trial results. N Engl J Med. 2021;384:497\u2013511. https:\/\/doi.org\/10.1056\/NEJMoa2023184.","journal-title":"N Engl J Med"},{"issue":"9","key":"1091_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"JH Beigel","year":"2021","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19\u2014final report. N Engl J Med. 2021;384(9):795\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa2031994.","journal-title":"N Engl J Med"},{"issue":"5","key":"1091_CR11","doi-asserted-by":"publisher","first-page":"663","DOI":"10.7326\/M20-8148","volume":"174","author":"AS Kaka","year":"2021","unstructured":"Kaka AS, MacDonald R, Greer N, Vela K, Duan-Porter W, Obley A, et al. Major update: remdesivir for adults with COVID-19: a living systematic review and meta-analysis for the American College of Physicians Practice Points. Ann Intern Med. 2021;174(5):663\u201372. https:\/\/doi.org\/10.7326\/M20-8148.","journal-title":"Ann Intern Med"},{"key":"1091_CR12","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/17512433.2020.1821650","volume":"13","author":"A Saint-Raymond","year":"2020","unstructured":"Saint-Raymond A, Sato J, Kishioka Y, Teixeira T, Hasslboeck C, Kweder SL. Remdesivir emergency approvals: a comparison of the U.S., Japanese, and EU systems. Expert Rev Clin Pharmacol. 2020;13:1095\u2013101.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1091_CR13","unstructured":"Staff R. FACTBOX-Countries where remdesivir is approved or supported for treating COVID-19. Reuters. 2020 Jul 10. https:\/\/www.reuters.com\/article\/healthcoronavirus-gilead-remdesivir-idUSL4N2EA2LZ. Accessed 20 Jan 2021."},{"key":"1091_CR14","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","volume":"6","author":"RT Eastman","year":"2020","unstructured":"Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci. 2020;6:672\u201383.","journal-title":"ACS Cent Sci"},{"key":"1091_CR15","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/cpt.2145","volume":"109","author":"AO G\u00e9rard","year":"2021","unstructured":"G\u00e9rard AO, Laurain A, Fresse A, Parassol N, Muzzone M, Rocher F, et al. Remdesivir and acute renal failure: a potential safety signal from disproportionality analysis of the who safety database. Clin Pharmacol Ther. 2021;109:1021\u20134.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1091_CR16","doi-asserted-by":"publisher","first-page":"791.e5","DOI":"10.1016\/j.cmi.2021.02.013","volume":"27","author":"A Touafchia","year":"2021","unstructured":"Touafchia A, Bagheri H, Carri\u00e9 D, Durrieu G, Sommet A, Chouchana L, et al. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2021;27(5):791.e5-791.e8. https:\/\/doi.org\/10.1016\/j.cmi.2021.02.013.","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis."},{"key":"1091_CR17","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.kint.2021.02.015","volume":"99","author":"L Chouchana","year":"2021","unstructured":"Chouchana L, Preta L-H, Tisseyre M, Terrier B, Treluyer J-M, Montastruc F. Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019: a retrospective case-noncase study. Kidney Int. 2021;99:1235\u20136.","journal-title":"Kidney Int"},{"key":"1091_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/17512433.2021.1856655","volume":"14","author":"J Charan","year":"2021","unstructured":"Charan J, Kaur RJ, Bhardwaj P, Haque M, Sharma P, Misra S, et al. Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. Expert Rev Clin Pharmacol. 2021;14:95\u2013103.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1091_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO Global ICSR database system: basic facts. Ther Innov Regul Sci. 2008;42:409\u201319. https:\/\/doi.org\/10.1177\/009286150804200501.","journal-title":"Ther Innov Regul Sci"},{"key":"1091_CR20","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s11096-018-0694-9","volume":"40","author":"SK Behera","year":"2018","unstructured":"Behera SK, Das S, Xavier AS, Velupula S, Sandhiya S. Comparison of different methods for causality assessment of adverse drug reactions. Int J Clin Pharm. 2018;40:903\u201310.","journal-title":"Int J Clin Pharm"},{"key":"1091_CR21","doi-asserted-by":"crossref","unstructured":"Zekarias A, Watson S, Vidlin SH, Grundmark B. Sex differences in reported adverse drug reactions to COVID-19 drugs in a global database of individual case safety reports. Drug Saf. 2020;43(12):1309\u201314.","DOI":"10.1007\/s40264-020-01000-8"},{"key":"1091_CR22","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S0140-6736(20)31863-8","volume":"396","author":"CE Oldenburg","year":"2020","unstructured":"Oldenburg CE, Doan T. Azithromycin for severe COVID-19. The Lancet Elsevier. 2020;396:936\u20137.","journal-title":"The Lancet. Elsevier"},{"key":"1091_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40264-013-0131-x","volume":"37","author":"T Bergvall","year":"2014","unstructured":"Bergvall T, Nor\u00e9n GN, Lindquist M. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37:65\u201377.","journal-title":"Drug Saf"},{"key":"1091_CR24","unstructured":"NIH. Clinical Spectrum of SARS-CoV-2 Infection. COVID-19 Treat. Guidel. 2021. https:\/\/www.covid19treatmentguidelines.nih.gov\/overview\/clinical-spectrum\/. Accessed 24 Feb 2021."},{"key":"1091_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22:57\u201369.","journal-title":"Stat Methods Med Res"},{"key":"1091_CR26","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00228-014-1658-1","volume":"70","author":"B Grundmark","year":"2014","unstructured":"Grundmark B, Holmberg L, Garmo H, Zethelius B. Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area. Eur J Clin Pharmacol. 2014;70:627\u201335. https:\/\/doi.org\/10.1007\/s00228-014-1658-1.","journal-title":"Eur J Clin Pharmacol"},{"key":"1091_CR27","unstructured":"European Medicines Agency. Summary of product characteristics for Roactemra 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/roactemra-epar-product-information_en.pdf Accessed23 Feb 2021."},{"key":"1091_CR28","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. R Proj. Stat. Comput. 2017. https:\/\/www.r-project.org\/. Accessed 20 May 2021."},{"key":"1091_CR29","unstructured":"Council for International Organizations of Medical Sciences, editor. Reporting adverse drug reactions: definitions of terms and criteria for their use. Repr. Geneva: CIOMS; 2000."},{"key":"1091_CR30","doi-asserted-by":"publisher","first-page":"e0008412","DOI":"10.1371\/journal.pntd.0008412","volume":"14","author":"DE McMahon","year":"2020","unstructured":"McMahon DE, Peters GA, Ivers LC, Freeman EE. Global resource shortages during COVID-19: Bad news for low-income countries. PLoS Negl Trop Dis. 2020;14:e0008412.","journal-title":"PLoS Negl Trop Dis"},{"key":"1091_CR31","unstructured":"COVID-19 Hospitalizations. Centers For Disease Control and Prevention. 2021. https:\/\/gis.cdc.gov\/grasp\/covidnet\/COVID19_5.html. Accessed 23 Feb 2021."},{"key":"1091_CR32","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/phar.2464","volume":"40","author":"C Carothers","year":"2020","unstructured":"Carothers C, Birrer K, Vo M. Acetylcysteine for the treatment of suspected remdesivir-associated acute liver failure in COVID-19: a case series. Pharmacother J Hum Pharmacol Drug Ther. 2020;40:1166\u201371.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther."},{"key":"1091_CR33","unstructured":"Centers for Disease Control and Prevention. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). Cent. Dis. Control Prev. 2020. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-guidance-management-patients.html Accessed 1 Mar 2021."},{"key":"1091_CR34","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, RECOVERY Collaborative Group, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693\u2013704.","journal-title":"N Engl J Med"},{"issue":"11","key":"1091_CR35","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3389\/fphar.2020.01124","volume":"6","author":"P Paolisso","year":"2020","unstructured":"Paolisso P, Bergamaschi L, D\u2019Angelo EC, Donati F, Giannella M, Tedeschi S, et al. Preliminary experience with low molecular weight heparin strategy in COVID-19 patients. Front Pharmacol. 2020;6(11):1124. https:\/\/doi.org\/10.3389\/fphar.2020.01124.","journal-title":"Front Pharmacol"},{"key":"1091_CR36","doi-asserted-by":"publisher","first-page":"230","DOI":"10.4239\/wjd.v5.i3.230","volume":"5","author":"F Bilotta","year":"2014","unstructured":"Bilotta F, Guerra C, Badenes R, Lolli S, Rosa G. Short acting insulin analogues in intensive care unit patients. World J Diabetes. 2014;5:230\u20134.","journal-title":"World J Diabetes"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01091-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-021-01091-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01091-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T15:27:40Z","timestamp":1629214060000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-021-01091-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1091"],"URL":"https:\/\/doi.org\/10.1007\/s40264-021-01091-x","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,10]]},"assertion":[{"value":"24 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Elena Rocca, Oskar Gauffin, Ruth Savage, Sara Hedfors Vidlin and Birgitta Grundmark declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"No external sources of funding were used to assist in the preparation of this study. Funding for the study being published with open access has been provided by the Uppsala Monitoring Centre.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and analysed during the current study are not publicly available due to agreements between contributors of data to the database used (VigiBase) and the custodian of this database. National centres (mainly national drug regulatory authorities) constituting the WHO Programme for International Drug Monitoring (PIDM) contribute data to VigiBase and the Uppsala Monitoring Centre is the custodian in its capacity as the WHO Collaborating Centre for International Drug Monitoring. Some subsets of the data may be available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The code used for the current study is not provided.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"BG, RS and OG conceived of the presented idea. All authors designed and developed the study together. OG and SV performed the algorithm development and the computations. All authors discussed results and contributed to the writing of the final manuscript. All authors read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}